Newsletter | December 8, 2025

12.08.25 -- New Technical Insights To Elevate Your CDO Programs

Optimizing Charge And N-glycan Profiles For CHO-Derived Fusion Proteins

For recombinant biologics, product quality attributes play a critical role in determining efficacy, clearance, and immunogenicity. Discover how structured design-of-experiment approaches can provide deeper insight into process control and therapeutic performance.

 

From Cell Line Development To Upstream Optimization: Enhancing Biologics Quality And Productivity

Efficient biologics manufacturing hinges on high-titer, high-quality cell lines. Explore how advanced cell line development and upstream processing strategies optimize both productivity and therapeutic effectiveness, ensuring the development of high-quality biologics.

 

Advancing Biologics Development With Next-Gen Cell Line Development

Next-generation cell line development utilizes transposase-mediated integration for speed and stability. It also employs an engineered cell line to enhance ADCC and a high-throughput assay for early glycosylation control, streamlining the development of complex biologics.

 

SOLUTIONS

 

Samsung Biologics - Your Program. Our Priority.

Samsung Biologics is a fully integrated, end-to-end CDMO partner offering seamless development and manufacturing services from cell line development to final aseptic fill/finish for biologics. Keeping the highest standards of commercialization in mind, we expand our development portfolio and continue to offer the most optimized service to fit client’s needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.

 

•  Download Samsung Biologics Corporate Brochure

•  Download Samsung Biologics CDO Brochure

•  Download Samsung Biologics ADC Brochure

 

Request Information